RECEIVED CENTRAL FAX CENTER

6123599349

P.11

APR 1 1 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Lex P. Jansen et al.

Confirmation No.: 6058

Serial No.:

10/079,103

Examiner: L. Thanh

Filing Date:

February 19, 2002

Group Art Unit: 3763

Docket No.:

1001.1682102

Customer No.: 28075

For:

CATHETER WITH COMPOSITE STIFFENER

Mail Stop Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

TERMINAL DISCLAIMER TO OBVIATE DOUBLE PATENTING REJECTION OVER A PRIOR PATENT (37 C.F.R. 1.321(c))

CERTIFICATE OF FACSIMILE TRANSMISSION UNDER 37 C.F.R. §1.8 (1(1)(8))
I hereby certify that this correspondence is being transmitted by facsimile to the United States Patent and Trademark Office

Type or print name of person signing certification

at 703-872-9306 on the date shown below.

Kattley & Baskley

April 11, 2005

Date

The owner, Target Therapeutics, Inc., of full interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,368,316. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent

Appl. No. 10/079,103

Term. Discl. dated April 11, 2005

Reply to Office Action of January 14, 2005

granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

The undersigned is an attorney of record.

Permission is hereby granted to charge the terminal disclaimer fee of \$130 to Deposit Account No. 50-0413. Permission is hereby granted to charge any deficiency or overpayment to Deposit Account No. 50-0413.

Respectfully submitted,

TARGET THERAPEUTICS, INC.

D-4-.

David M. Crompton, Reg. No.

CROMPTON, SEAGER & TUFFE, LLC

1221 Nicollet Avenue, Suite 800

Minneapolis, Minnesota 55403-2420

Telephone:

By its Attorney

(612) 677-9050

Facsimile:

(612) 359-9349